Sarepta jumps after announcing expanded approval of DMD drug and more news on today's top movers.

Check out this morning's top movers from around Wall Street, compiled by The Fly. 
 

HIGHER -

• Sarepta (SRPT) up 35% after announcing expanded FDA approval of Elevidys for Duchenne muscular dystrophy
• Nike (NKE) up 2% after Oppenheimer upgraded the stock to Outperform, saying that multiples at which shares trade and nearer-term financial expectations are now largely "derisked" and poised to rebound gradually
• Gilead (GILD) up another 4% after yesterday announcing topline results from an interim analysis of its pivotal, Phase 3 PURPOSE 1 trial indicating that the company's twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, demonstrated 100% efficacy for the investigational use of HIV prevention in cisgender women

UP AFTER EARNINGS -

• Carmax (KMX) up 2%
• FactSet (FDS) up 3
• Algoma Steel (ASTL) up 5%

LOWER -

• Hims & Hers (HIMS) down 10% after Eli Lilly (LLY) said Thursday it was suing six more entities including medical spas and wellness centers for selling products claiming to contain tirzepatide, the active ingredient in its popular diabetes drug, Mounjaro
• Palantir (PLTR) down 1% after being downgraded to Sell at Monness Crespi, which cited "gluttonous valuation"
• CME Group (CME) down 1% after being downgraded to Underweight at JPMorgan, which said FMX is entering the U.S. interest rate futures market in late summer and will compete with CME in its flagship futures contracts

More By This Author:

Qualcomm Under Pressure Following Issues With New Samsung AI Laptop
Opening Day: Google-Backed Tempus AI rises in Nasdaq debut
Wall Street's Top 10 Stock Calls This Week - Saturday, June 15